240 related articles for article (PubMed ID: 15472001)
1. In vitro activity of ertapenem against selected respiratory pathogens.
Marchese A; Gualco L; Schito AM; Debbia EA; Schito GC
J Antimicrob Chemother; 2004 Nov; 54(5):944-51. PubMed ID: 15472001
[TBL] [Abstract][Full Text] [Related]
2. [In vitro activity of trovafloxacin in 238 respiratory pathogens].
Alarcón T; Domingo D; Prieto N; Sánchez S; López-Brea M
Rev Esp Quimioter; 1998 Mar; 11(1):47-51. PubMed ID: 9795289
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of ertapenem against drug-resistant Streptococcus pneumoniae and other respiratory pathogens from 12 Asian countries.
Song JH; Ko KS; Lee MY; Park S; Baek JY; Lee JY; Heo ST; Kwon KT; Ryu SY; Oh WS; Peck KR; Lee NY
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):445-50. PubMed ID: 16949783
[TBL] [Abstract][Full Text] [Related]
4. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
6. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN;
J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
[TBL] [Abstract][Full Text] [Related]
7. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens].
Prado V; Giangrieco M; Durán C; Ojeda A; van Flaskamp R
Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240
[TBL] [Abstract][Full Text] [Related]
8. [Antimicrobial susceptibility of Streptococcus pyogenes, Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis from community acquired respiratory infections in 2000].
Melo-Cristino J; Fernandes ML; Serrano N;
Acta Med Port; 2001; 14(5-6):459-68. PubMed ID: 11878155
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.
Brown SD; Rybak MJ
J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i7-15. PubMed ID: 15265831
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of ertapenem: review of recent studies.
Wexler HM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
[TBL] [Abstract][Full Text] [Related]
12. PROTEKT 1999-2000: a multicentre study of the antimicrobial susceptibility of respiratory tract pathogens in Japan.
Inoue M; Kohno S; Kaku M; Yamaguchi K; Igari J; Yamanaka K
Int J Infect Dis; 2005 Jan; 9(1):27-36. PubMed ID: 15603993
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of cefditoren: antimicrobial efficacy against major respiratory pathogens from Asian countries.
Lee MY; Ko KS; Oh WS; Park S; Lee JY; Baek JY; Suh JY; Peck KR; Lee NY; Song JH
Int J Antimicrob Agents; 2006 Jul; 28(1):14-8. PubMed ID: 16777383
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model.
Zhanel GG; Derkatch S; Laing N; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2007 Jan; 59(1):144-7. PubMed ID: 17079238
[TBL] [Abstract][Full Text] [Related]
15. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
Jones RN; Fritsche TR; Sader HS; Stilwell MG
Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial activity of carbapenems against clinically isolated respiratory bacterial pathogens in Japan between 2005 and 2006.
Gomi K; Watanabe A; Aoki S; Kikuchi T; Fuse K; Nukiwa T; Kurokawa I; Fujimura S
Int J Antimicrob Agents; 2007 May; 29(5):586-92. PubMed ID: 17387003
[TBL] [Abstract][Full Text] [Related]
17. In vitro antibacterial activities of S-013420, a novel bicyclolide, against respiratory tract pathogens.
Homma T; Fujimura T; Maki H; Yamano Y; Shimada J; Kuwahara S
J Antimicrob Chemother; 2010 Jul; 65(7):1433-40. PubMed ID: 20472695
[TBL] [Abstract][Full Text] [Related]
18. In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698.
Lofland D; Difuntorum S; Waller A; Clements JM; Weaver MK; Karlowsky JA; Johnson K
J Antimicrob Chemother; 2004 Apr; 53(4):664-8. PubMed ID: 14973152
[TBL] [Abstract][Full Text] [Related]
19. Resistance patterns of selected respiratory tract pathogens in Poland.
Skoczyńska A; Kadłubowski M; Waśko I; Fiett J; Hryniewicz W
Clin Microbiol Infect; 2007 Apr; 13(4):377-83. PubMed ID: 17359321
[TBL] [Abstract][Full Text] [Related]
20. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
Wallrauch-Schwarz C; Milatovic D; Braveny I
Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
